

Amendments to the Claims

Following is a complete listing of the claims pending in the application:

1. (Currently amended) A method of decreasing IFN- γ blood levels in a subject with an elevated IFN- γ blood level due to administration of a therapeutic agent for treating multiple sclerosis, comprising

orally administering an interferon-tau (IFN τ) having greater than about 80% homology to ovine interferon-tau about 90% sequence identity to SEQ ID NO:2 at a dosage of between 6×10^8 – 5×10^{12} Units to decrease the subject's IFN- γ blood level relative to the IFN- γ blood level in the absence of IFN τ administration.

2. (Cancelled)

3. (Previously presented) The method of claim 1, wherein said IFN τ has a sequence identified as SEQ ID NO:2 or SEQ ID NO:3.

4. (Previously presented) The method of claim 1, wherein said orally administering is to a subject having an elevated IFN- γ level due to administration of the therapeutic agent interferon-beta.

5-11. (Cancelled)